Clinical trialNCT06855277RecruitingPhase 3Interventional

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

SponsorNovartis PharmaceuticalsEnrollment940Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

70 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia
Recruiting

Brazil

Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting

China

Novartis Investigative Site
Fuzhou, Fujian, China
Recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China
Recruiting
Novartis Investigative Site
Wuhan, Hubei, China
Recruiting
Novartis Investigative Site
Wuhan, Hubei, China
Recruiting
Novartis Investigative Site
Nanjing, Jiangsu, China
Recruiting
Novartis Investigative Site
Nanjing, Jiangsu, China
Recruiting
Novartis Investigative Site
Shenyang, Liaoning, China
Recruiting
Novartis Investigative Site
Chengdu, Sichuan, China
Recruiting
Novartis Investigative Site
Hangzhou, Zhejiang, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Guangzhou, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting
Novartis Investigative Site
Tianjin, China
Recruiting

Hong Kong

Novartis Investigative Site
Hong Kong, Hong Kong
Recruiting

India

Novartis Investigative Site
Gurgaon, Haryana, India
Recruiting
Novartis Investigative Site
Bengaluru, Karnataka, India
Recruiting
Novartis Investigative Site
Mumbai, Maharashtra, India
Recruiting

Japan

Novartis Investigative Site
Sapporo, Hokkaido, Japan
Recruiting
Novartis Investigative Site
Kobe, Hyōgo, Japan
Recruiting
Novartis Investigative Site
Kobe, Hyōgo, Japan
Recruiting
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Recruiting
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Recruiting
Novartis Investigative Site
Chiba, Japan
Recruiting
Novartis Investigative Site
Fukuoka, Japan
Recruiting
Novartis Investigative Site
Fukuoka, Japan
Recruiting
Novartis Investigative Site
Fukuoka, Japan
Recruiting
Novartis Investigative Site
Fukushima, Japan
Recruiting
Novartis Investigative Site
Hiroshima, Japan
Recruiting
Novartis Investigative Site
Kyoto, Japan
Recruiting

Singapore

Novartis Investigative Site
Singapore, Singapore
Recruiting
Novartis Investigative Site
Singapore, Singapore
Recruiting
Novartis Investigative Site
Singapore, Singapore
Recruiting

South Korea

Novartis Investigative Site
Seoul, South Korea
Recruiting

30 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Actinium(225Ac) Vipivotide Tetraxetan →ARPI →Standard of Care

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Jul 2025
Primary completion: 29 Sept 2028
Completion: 4 Nov 2032
Last update posted: 10 Jun 2026
Registered enrollment: 940
Registry id: NCT06855277

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-512340-32

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.